Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
This week Dana Jennings writes about the fatigue that he and many men with more advanced forms of prostate cancer feel — from the cancer itself and also from the treatments needed to keep it under as much control as possible.
Filed under: Living with Prostate Cancer | Tagged: Dana Jennings, fatigue | Leave a Comment »
The American Cancer Society has just released its biannual publication Cancer Facts and Figures in African Americans, 2009-2010. However, publication of the complete Cancer Facts and Figures 2009, which is normally published by early February each year, “has been delayed due to the late release of the US final mortality for 2006 by the National [...]
Filed under: Diagnosis, Risk | Tagged: African American, incidence, mortality | Leave a Comment »
Today’s news reports contain two articles (on adjuvant radiotherapy in men progressing after first-line surgical treatment and on thalidomide in combination with intermittent androgen deprivation) that were discussed last month on this blog. Two additional articles are of clinical interest, but most of today’s news reports again fall into the “dense” scientific category.
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: coregulators, Diagnosis, HIFU, high-intensity focused ultrasound, mortality, MRI, physical activity, segmentation, Sprouty1 expression, urethral stricture formation | Leave a Comment »
In developing our earlier article on the PCA3 test (on Sunday), we should have made it clear that, despite the fact that Gen-Probe’s Progensa PCA3 assay is not yet commercially available in the USA, it absolutely is possible for patients to have the PCA3 test carried out — and in most cases this will be [...]
Filed under: Diagnosis, Management | Tagged: PCA3 assay availability coverage | Leave a Comment »
“Several men treated for impotence” at a clinic in Minnesota apparently “wound up in the emergency room with painful and embarrassing complications that, local urologists say, were the result of inappropriate and irresponsible care.”
Filed under: Living with Prostate Cancer, Management | Tagged: caution, impotence, risk | 1 Comment »
For the engineers, the scientists, and other technically minded readers, there are a number of very “dense” scientific news reports today.
Filed under: Diagnosis, Management, Treatment | Tagged: circulating tumor cells, CTC, MRI, OCT, optical coherence tomography, segmentation | 2 Comments »
There is a very interesting article in the Baltimore Sun today about the role of active surveillance as a management strategy for prostate cancer — particularly for men of 60 and older.
Filed under: Living with Prostate Cancer, Management | Tagged: active surveillance | Leave a Comment »
There is a reasonably extensive literature on the possible association between mutations to the Y-chromosome and risk for prostate cancer. And for those readers who need a reminder, the major distinction, at a genetic level, between men and women is that men have one X- and one Y-chromosome, whereas women have two X-chromosomes.
Filed under: Risk | Tagged: daughters, risk, Y-chromosome | Leave a Comment »
The PCA3 or prostate cancer gene 3 assay was approved some time ago for commercial use in Europe. It has not yet been approved by the U.S. Food and Drug Administration. What are the real differences between this test and the PSA test that we are all more accustomed too?
Filed under: Diagnosis, Management | Tagged: PCA3, prostate cancer gene 3 | 5 Comments »
… CALL YOUR SENATORS AND YOUR CONGRESSPERSON!
Filed under: Uncategorized | Comments Off
Since (after yesterday’s glut) there appear to be no new news reports for the weekend, we thought it might be useful to offer a little education on so-called “micro RNAs” and their potential roles in prostate cancer.
Filed under: Diagnosis, Drugs in development, Management, Prevention, Risk, Treatment | Tagged: micro RNA, miRNA | 1 Comment »
A report published by Reuters within the past couple of hours makes some surprisingly assertive claims about the safety of (unspecified forms of) “radiation therapy” in the treatment of prostate cancer. These claims are all the worse for being based on retrospective analysis as opposed to any sort of prospective clinical trial.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: adverse events, radiation therapy, short-term, surgery | Leave a Comment »
The second set of reports in today’s news commentaries encompasses new nomograms, possible new biomarkers, a specific subtype of prostate cancer, and the “hedgehog” signaling pathway.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: biomarkers, ETS fusion, hedgehog signaling, ionized serum calcium, nomogram, recurrence, surgeon experience, survival | Leave a Comment »
After a relatively quiet news period, the flood gates have opened again, so we shall divide today’s news reports into two postings for easier reading. We have also published a separate report on the possibility of an association between alcohol use and prostate cancer diagnosis.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: active surveillance, aggressiveness, androgen resistance, avanafil, ED, erectile dysfunction, p63, prognosis, survival, vitamin D | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site